These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 27565680)
61. Regulation of peroxisome proliferator-activated receptors (PPAR) α and -γ of rat brain astrocytes in the course of activation by toll-like receptor agonists. Chistyakov DV; Aleshin SE; Astakhova AA; Sergeeva MG; Reiser G J Neurochem; 2015 Jul; 134(1):113-24. PubMed ID: 25818681 [TBL] [Abstract][Full Text] [Related]
62. Picrasidine N Is a Subtype-Selective PPARβ/δ Agonist. Zhao S; Kanno Y; Li W; Wakatabi H; Sasaki T; Koike K; Nemoto K; Li H J Nat Prod; 2016 Apr; 79(4):879-85. PubMed ID: 27025413 [TBL] [Abstract][Full Text] [Related]
63. Peroxisome proliferator-activated receptor γ agonists induce cell cycle arrest through transcriptional regulation of Kruppel-like factor 4 (KLF4). Li S; Zhou Q; He H; Zhao Y; Liu Z J Biol Chem; 2013 Feb; 288(6):4076-84. PubMed ID: 23275339 [TBL] [Abstract][Full Text] [Related]
64. Identification of a peroxisome proliferator-responsive element upstream of the human peroxisomal fatty acyl coenzyme A oxidase gene. Varanasi U; Chu R; Huang Q; Castellon R; Yeldandi AV; Reddy JK J Biol Chem; 1996 Jan; 271(4):2147-55. PubMed ID: 8567672 [TBL] [Abstract][Full Text] [Related]
66. Role of PPARalpha in mediating the effects of phthalates and metabolites in the liver. Lapinskas PJ; Brown S; Leesnitzer LM; Blanchard S; Swanson C; Cattley RC; Corton JC Toxicology; 2005 Feb; 207(1):149-63. PubMed ID: 15590130 [TBL] [Abstract][Full Text] [Related]
67. Interaction of the peroxisome proliferator-activated receptor alpha with the retinoid X receptor alpha unmasks a cryptic peroxisome proliferator response element that overlaps an ARP-1-binding site in the CYP4A6 promoter. Palmer CN; Hsu MH; Muerhoff AS; Griffin KJ; Johnson EF J Biol Chem; 1994 Jul; 269(27):18083-9. PubMed ID: 8027069 [TBL] [Abstract][Full Text] [Related]
68. Human NPC1L1 expression is positively regulated by PPARα. Iwayanagi Y; Takada T; Tomura F; Yamanashi Y; Terada T; Inui K; Suzuki H Pharm Res; 2011 Feb; 28(2):405-12. PubMed ID: 20953676 [TBL] [Abstract][Full Text] [Related]
69. Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)α/γ agonist aleglitazar in attenuating TNF-α-mediated inflammation and insulin resistance in human adipocytes. Massaro M; Scoditti E; Pellegrino M; Carluccio MA; Calabriso N; Wabitsch M; Storelli C; Wright M; De Caterina R Pharmacol Res; 2016 May; 107():125-136. PubMed ID: 26976796 [TBL] [Abstract][Full Text] [Related]
70. Integrated virtual screening for the identification of novel and selective peroxisome proliferator-activated receptor (PPAR) scaffolds. Nevin DK; Peters MB; Carta G; Fayne D; Lloyd DG J Med Chem; 2012 Jun; 55(11):4978-89. PubMed ID: 22582973 [TBL] [Abstract][Full Text] [Related]
71. Simultaneous, bidirectional inhibitory crosstalk between PPAR and STAT5b. Shipley JM; Waxman DJ Toxicol Appl Pharmacol; 2004 Sep; 199(3):275-84. PubMed ID: 15364543 [TBL] [Abstract][Full Text] [Related]
72. Down-regulation of STAT5b transcriptional activity by ligand-activated peroxisome proliferator-activated receptor (PPAR) alpha and PPARgamma. Shipley JM; Waxman DJ Mol Pharmacol; 2003 Aug; 64(2):355-64. PubMed ID: 12869640 [TBL] [Abstract][Full Text] [Related]
73. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia. Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517 [TBL] [Abstract][Full Text] [Related]
74. Peroxisome-proliferator-activated receptor alpha agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1. Grau R; Punzón C; Fresno M; Iñiguez MA Biochem J; 2006 Apr; 395(1):81-8. PubMed ID: 16343055 [TBL] [Abstract][Full Text] [Related]
75. Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta. Evans JL; Lin JJ; Goldfine ID Curr Diabetes Rev; 2005 Aug; 1(3):299-307. PubMed ID: 18220606 [TBL] [Abstract][Full Text] [Related]
76. Huangkui capsule, an extract from Abelmoschus manihot (L.) medic, improves diabetic nephropathy via activating peroxisome proliferator-activated receptor (PPAR)-α/γ and attenuating endoplasmic reticulum stress in rats. Ge J; Miao JJ; Sun XY; Yu JY J Ethnopharmacol; 2016 Aug; 189():238-49. PubMed ID: 27224243 [TBL] [Abstract][Full Text] [Related]
77. Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor gamma in human lung carcinoma cells. Han S; Sidell N; Fisher PB; Roman J Clin Cancer Res; 2004 Mar; 10(6):1911-9. PubMed ID: 15041706 [TBL] [Abstract][Full Text] [Related]
78. G Protein-coupled Receptor 40 (GPR40) and Peroxisome Proliferator-activated Receptor γ (PPARγ): AN INTEGRATED TWO-RECEPTOR SIGNALING PATHWAY. Wang S; Awad KS; Elinoff JM; Dougherty EJ; Ferreyra GA; Wang JY; Cai R; Sun J; Ptasinska A; Danner RL J Biol Chem; 2015 Aug; 290(32):19544-57. PubMed ID: 26105050 [TBL] [Abstract][Full Text] [Related]
79. Functional characterization of the 5' flanking region of the BACE gene: identification of a 91 bp fragment involved in basal level of BACE promoter expression. Ge YW; Maloney B; Sambamurti K; Lahiri DK FASEB J; 2004 Jun; 18(9):1037-9. PubMed ID: 15059977 [TBL] [Abstract][Full Text] [Related]
80. PPARs as therapeutic targets in cardiovascular disease. van Bilsen M; van Nieuwenhoven FA Expert Opin Ther Targets; 2010 Oct; 14(10):1029-45. PubMed ID: 20854178 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]